- Home
- PULM vs DRIO Comparison
PULM vs DRIO Comparison
Compare PULM & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- DRIO
- Stock Information
- Founded
- PULM 2003
- DRIO 2011
- Country
- PULM United States
- DRIO United States
- Employees
- PULM N/A
- DRIO N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- DRIO Medical/Dental Instruments
- Sector
- PULM Health Care
- DRIO Health Care
- Exchange
- PULM Nasdaq
- DRIO Nasdaq
- Market Cap
- PULM 33.2M
- DRIO 31.1M
- IPO Year
- PULM N/A
- DRIO N/A
- Fundamental
- Price
- PULM $7.43
- DRIO $0.70
- Analyst Decision
- PULM
- DRIO Strong Buy
- Analyst Count
- PULM 0
- DRIO 2
- Target Price
- PULM N/A
- DRIO $2.50
- AVG Volume (30 Days)
- PULM 34.2K
- DRIO 161.2K
- Earning Date
- PULM 08-12-2025
- DRIO 08-07-2025
- Dividend Yield
- PULM N/A
- DRIO N/A
- EPS Growth
- PULM N/A
- DRIO N/A
- EPS
- PULM N/A
- DRIO N/A
- Revenue
- PULM $1,921,000.00
- DRIO $28,034,000.00
- Revenue This Year
- PULM N/A
- DRIO $13.66
- Revenue Next Year
- PULM $134.88
- DRIO $24.50
- P/E Ratio
- PULM N/A
- DRIO N/A
- Revenue Growth
- PULM N/A
- DRIO 47.20
- 52 Week Low
- PULM $1.78
- DRIO $0.50
- 52 Week High
- PULM $10.40
- DRIO $1.55
- Technical
- Relative Strength Index (RSI)
- PULM 49.28
- DRIO 53.98
- Support Level
- PULM $8.49
- DRIO $0.67
- Resistance Level
- PULM $8.75
- DRIO $0.72
- Average True Range (ATR)
- PULM 0.42
- DRIO 0.04
- MACD
- PULM -0.14
- DRIO 0.00
- Stochastic Oscillator
- PULM 0.11
- DRIO 70.79
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About DRIO DarioHealth Corp.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. Its cross-functional team operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and engaging digital therapeutics interventions. Also platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.